Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.
作者信息
Passaro Antonio, Cortot Alexis B, Gentzler Ryan D, Reckamp Karen L, Shah Sujay, William William Nassib, Cho Byoung Chul
机构信息
aDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
bUniversity of Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.
出版信息
Future Oncol. 2025 Jun;21(13):1553-1568. doi: 10.1080/14796694.2025.2492456. Epub 2025 May 6.
Abstract
摘要
相似文献
1
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.MARIPOSA-2的通俗易懂总结：阿美替尼单抗联合化疗，无论是否联合拉泽替尼用于治疗非小细胞肺癌。
Future Oncol. 2025 Jun;21(13):1553-1568. doi: 10.1080/14796694.2025.2492456. Epub 2025 May 6.
2
Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA.MARIPOSA研究中一线使用阿美替尼联合拉泽替尼治疗既往未治疗的高危表皮生长因子受体（EGFR）改变的非小细胞肺癌的通俗概述
Future Oncol. 2025 May;21(12):1429-1444. doi: 10.1080/14796694.2025.2487407. Epub 2025 Apr 24.
3
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Amivantamab 联合化疗加或不加 lazertinib 治疗奥希替尼治疗后进展的 EGFR 突变型晚期 NSCLC：III 期 MARIPOSA-2 研究的主要结果。
Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
4
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.阿美替尼治疗转移性非小细胞肺癌：患者选择与特殊考量
Onco Targets Ther. 2022 Oct 12;15:1197-1210. doi: 10.2147/OTT.S329095. eCollection 2022.
5
Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated -mutated non-small-cell lung cancer.PAPILLON的通俗易懂总结：在未经治疗的EGFR外显子20插入突变的非小细胞肺癌中使用阿米万他单抗联合化疗。 （注：原文中mutated前少了EGFR外显子20插入相关内容，根据语境推测补充完整以保证翻译逻辑通顺）
Future Oncol. 2024;20(32):2409-2421. doi: 10.1080/14796694.2024.2371698. Epub 2024 Jul 16.
6
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Amivantamab 联合 lazertinib 对比奥希替尼用于具有高风险疾病生物标志物的一线治疗 EGFR 突变型晚期非小细胞肺癌：MARIPOSA 的一项二次分析。
Ann Oncol. 2024 Sep;35(9):805-816. doi: 10.1016/j.annonc.2024.05.541. Epub 2024 Jun 26.
7
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.MARIPOSA：一线 amivantamab + lazertinib 对比奥希替尼用于 EGFR 突变非小细胞肺癌的 3 期研究。
Future Oncol. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16.
8
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.Amivantamab 联合 Lazertinib 治疗未经治的 - 突变型晚期 NSCLC。
N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26.
9
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.阿米万他单抗联合拉泽替尼与奥希替尼作为表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌一线治疗的疗效比较：MARIPOSA亚洲亚组研究
Lung Cancer. 2025 Mar 15;204:108496. doi: 10.1016/j.lungcan.2025.108496.
10
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.奥希替尼和铂类化疗进展后，埃万妥单抗联合拉泽替尼治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者：CHRYSALIS-2队列A的结果
J Thorac Oncol. 2025 May;20(5):651-664. doi: 10.1016/j.jtho.2024.12.029. Epub 2025 Jan 2.
Zotero 插件